Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Liberty Wealth Management LLC

Liberty Wealth Management LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 377.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 11,562 shares of the medical research company’s stock after acquiring an additional 9,141 shares during the period. Liberty Wealth Management LLC’s holdings in Amgen were worth $3,613,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in AMGN. Strategic Financial Concepts LLC acquired a new stake in Amgen in the 2nd quarter worth about $26,000. Horizon Financial Services LLC acquired a new stake in shares of Amgen in the first quarter worth approximately $28,000. United Community Bank purchased a new stake in Amgen in the fourth quarter valued at approximately $29,000. nVerses Capital LLC acquired a new position in Amgen during the second quarter worth approximately $31,000. Finally, Bbjs Financial Advisors LLC purchased a new position in Amgen during the second quarter worth approximately $33,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 0.7 %

AMGN stock opened at $322.70 on Monday. The company has a market capitalization of $173.40 billion, a P/E ratio of 45.79, a PEG ratio of 2.85 and a beta of 0.61. The firm has a 50 day simple moving average of $326.26 and a 200-day simple moving average of $302.38. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. Amgen Inc. has a twelve month low of $249.70 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The company had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. During the same period in the prior year, the business earned $5.00 earnings per share. Amgen’s revenue was up 20.1% on a year-over-year basis. On average, equities research analysts predict that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 2.79%. The ex-dividend date was Friday, August 16th. Amgen’s dividend payout ratio is presently 128.57%.

Analyst Ratings Changes

AMGN has been the subject of a number of research analyst reports. Jefferies Financial Group restated a “buy” rating and set a $380.00 price objective (up from $375.00) on shares of Amgen in a report on Wednesday, August 7th. Bank of America boosted their target price on Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Wells Fargo & Company cut shares of Amgen from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $320.00 to $335.00 in a research report on Wednesday, August 7th. Oppenheimer reissued an “outperform” rating and issued a $380.00 price objective on shares of Amgen in a research report on Wednesday, August 7th. Finally, TD Cowen raised their target price on shares of Amgen from $360.00 to $381.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Eleven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $327.28.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.